STAGE IV OVARIAN CANCER AJCC V8
Clinical trials for STAGE IV OVARIAN CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV OVARIAN CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV OVARIAN CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New drug combo targets Hard-to-Treat RAS cancers
Disease control OngoingThis study tests two targeted drugs, palbociclib and binimetinib, in people with cancers that have RAS mutations, including certain ovarian and pancreatic cancers. The goal is to see if the combination can slow cancer growth better than one drug alone. About 199 adults will take …
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug (BAY 1895344) combined with standard chemotherapy for people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, ovarian,…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New drug combo shows promise for advanced ovarian cancer
Disease control OngoingThis early-phase trial tests adding a targeted drug called ipatasertib to standard chemotherapy (paclitaxel and carboplatin) for people with stage III or IV ovarian cancer. The goal is to find the safest dose and see if the combination can better control tumor growth. About 25 pa…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Immunotherapy drug shows promise for hard-to-treat cancers with genetic flaws
Disease control OngoingThis study tests the drug pembrolizumab in people with advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. About 21 adults with metastatic or recurrent cancer took part. Pembrolizu…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in 59 people with advanced solid tumors, including melanoma, colorectal, ovarian, and k…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for rare ovarian cancer: could hormone therapy replace chemo?
Disease control OngoingThis study tests whether the hormone therapy letrozole alone works as well as chemotherapy (paclitaxel and carboplatin) followed by letrozole for people with stage II-IV low-grade serous ovarian, fallopian tube, or peritoneal cancer. About 450 participants will be randomly assign…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial tested the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they had surgery. The goal was to see if taking olaparib for two cycles could shrink tumors or stop them from growing. Olaparib works…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New app helps women with advanced cancer fight fear
Symptom relief OngoingThis study tests an online program called Day by Day for women with stage III or IV gynecologic cancer who have high fear of their cancer getting worse or coming back. The program teaches skills to manage anxiety and reframe worries. About 23 women will try the program for 12 wee…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 15, 2026 18:55 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will track these samples over time to learn how cancer changes and why some treatments stop working. The goal is to build a resource for futu…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:55 UTC
-
Online support for cancer fear: study withdrawn before it began
Knowledge-focused TerminatedThis study was designed to see if a virtual mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer coming back or getting worse. The program would have been compared to standard educational materials. However, the study w…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:17 UTC
-
Blood test may tame Chemo's nerve damage
Knowledge-focused TerminatedThis study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if adjusting the dose based on these levels could reduce nerve damage, a common and severe side effect. About 22 adults with various s…
Matched conditions: STAGE IV OVARIAN CANCER AJCC V8
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 01, 2026 18:03 UTC